BACKGROUND: Multiple sclerosis (MS) is an autoimmune disorder, with a considerable genetic influence on susceptibility and disease course. Cytokines play an important role in MS pathophysiology, and genes encoding various cytokines are logical candidates to assess possible associations with MS susceptibility and disease course. We previously reported an association of a combination of polymorphisms in the interleukin (IL)-1B and IL-1 receptor antagonist (IL-1RN) genes (i.e. IL-1RN allele 2+/IL-1B(+3959)allele 2-) with disease severity in MS. Extending this observation, we investigated whether IL-1beta and IL-1ra production differed depending on carriership of this gene combination. METHODS: Twenty MS patients and 20 controls were selected based upon carriership of the specific combination. In whole blood, in vitro IL-1beta and IL-1ra production was determined by enzyme-linked immunosorbent-assay after 6 and 24 h of stimulation with lipopolysaccharide. RESULTS: Carriers of the specific combination produced more IL-1ra, especially in MS patients, although not significantly. IL-1ra production was significantly higher in individuals homozygous for IL-1RN allele 2. In patients, Il-1ra production was higher and IL-1beta production lower compared with controls. In primary progressive patients, the IL-1beta /IL-1ra ratio was significantly lower than in relapsing-remitting patients. CONCLUSION: Our results suggest higher in vitro IL-1ra production in carriers of IL-1RN allele 2, with an indication of an allelic dose-effect relationship.
BACKGROUND:Multiple sclerosis (MS) is an autoimmune disorder, with a considerable genetic influence on susceptibility and disease course. Cytokines play an important role in MS pathophysiology, and genes encoding various cytokines are logical candidates to assess possible associations with MS susceptibility and disease course. We previously reported an association of a combination of polymorphisms in the interleukin (IL)-1B and IL-1 receptor antagonist (IL-1RN) genes (i.e. IL-1RN allele 2+/IL-1B(+3959)allele 2-) with disease severity in MS. Extending this observation, we investigated whether IL-1beta and IL-1ra production differed depending on carriership of this gene combination. METHODS: Twenty MSpatients and 20 controls were selected based upon carriership of the specific combination. In whole blood, in vitro IL-1beta and IL-1ra production was determined by enzyme-linked immunosorbent-assay after 6 and 24 h of stimulation with lipopolysaccharide. RESULTS: Carriers of the specific combination produced more IL-1ra, especially in MSpatients, although not significantly. IL-1ra production was significantly higher in individuals homozygous for IL-1RN allele 2. In patients, Il-1ra production was higher and IL-1beta production lower compared with controls. In primary progressive patients, the IL-1beta /IL-1ra ratio was significantly lower than in relapsing-remitting patients. CONCLUSION: Our results suggest higher in vitro IL-1ra production in carriers of IL-1RN allele 2, with an indication of an allelic dose-effect relationship.
Authors: Brigit A de Jong; Tom W J Huizinga; Eduard L E M Bollen; Bernard M J Uitdehaag; Gerlof P Th Bosma; Mark A van Buchem; Edmond J Remarque; Alexandra C S Burgmans; Nynke F Kalkers; Chris H Polman; Rudi G J Westendorp Journal: J Neuroimmunol Date: 2002-05 Impact factor: 3.478
Authors: C L A Mann; M B Davies; V L Stevenson; S M Leary; M D Boggild; C Ko Ko; P W Jones; A A Fryer; R C Strange; A J Thompson; C P Hawkins Journal: J Neuroimmunol Date: 2002-08 Impact factor: 3.478
Authors: T Mandrup-Poulsen; F Pociot; J Mølvig; L Shapiro; P Nilsson; T Emdal; M Røder; L L Kjems; C A Dinarello; J Nerup Journal: Diabetes Date: 1994-10 Impact factor: 9.461
Authors: R Feakes; S Sawcer; S Broadley; F Coraddu; R Roxburgh; J Gray; D Clayton; A Compston Journal: J Neuroimmunol Date: 2000-06-01 Impact factor: 3.478
Authors: Maja Živković; Ivana Kolić; Snežana Jesić; Ana Jotić; Aleksandra Stanković Journal: Clin Exp Otorhinolaryngol Date: 2018-02-14 Impact factor: 3.372
Authors: Alba Sánchez-Fernández; Stephanie Zandee; Jesús Amo-Aparicio; Marc Charabati; Alexandre Prat; Cecilia Garlanda; Elan Z Eisenmesser; Charles A Dinarello; Rubèn López-Vales Journal: Theranostics Date: 2021-01-01 Impact factor: 11.556
Authors: Reham A Ammar; Ahmed F Mohamed; Mohamed M Kamal; Marwa M Safar; Noha F Abdelkader Journal: Inflammopharmacology Date: 2022-04-01 Impact factor: 5.093